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Introduction
Recently, the dose-dependent bioactivation and detoxifica-
tion of estragole in different species, including human, has 
been studied by physiologically based kinetic (PBK) and 
dynamic (PBD) modeling (Punt et  al. 2008, 2009, 2016). 
The models defined for the human population were specific 
for Caucasians, since the parameters used to describe the 
kinetics were derived using samples from relevant tissues 
from Caucasian origin. Considering the rapid developments 
in food safety in the past decade in China, it is of impor-
tance to obtain insight into to what extent safety and risk 
assessments of chemicals performed for the Caucasian pop-
ulation would also apply to the Chinese population. Given 
the fact that race diversity might result in the variability of 
dose-response relationships affecting the safety and effi-
cacy of chemical exposures (Malinowski et  al. 2008), the 
absence of knowledge in this field implies that harmoniza-
tion in legislation on chemicals between regulatory bodies 
of Europe, USA and Asia is hampered. Several studies have 
shown ethnic differences in cytochrome P450 enzymes. 
Significant differences in reactions catalyzed by CYP1A2, 
CYP2C9, CYP2C19, and CYP2E1 in liver microsomes 
have been observed between Chinese and Caucasian sam-
ples (Yang et al. 2012). Barter et al. (2013) developed PBK 
models and used them for in vitro to in vivo extrapolation 
to predict the P450-mediated pharmacokinetics of selected 
drugs in the Chinese population. The results showed that 
Abstract Considering the rapid developments in food 
safety in the past decade in China, it is of importance to 
obtain insight into what extent safety and risk assess-
ments of chemicals performed for the Caucasian popula-
tion apply to the Chinese population. The aim of  the pre-
sent study was to determine physiologically based kinetic 
(PBK) modeling-based predictions for differences between 
Chinese and Caucasians in terms of metabolic bioactiva-
tion and detoxification of the food-borne genotoxic car-
cinogen estragole. The PBK models were defined based 
on kinetic constants for hepatic metabolism derived from 
in vitro incubations using liver fractions of the two ethnic 
groups, and used to evaluate the inter-ethnic differences in 
metabolic activation and detoxification of estragole. The 
models predicted that at realistic dietary intake levels, only 
0.02% of the dose was converted to the ultimate carcino-
genic metabolite 1′-sulfooxyestragole in Chinese subjects, 
whereas this amounted to 0.09% of the dose in Caucasian 
subjects. Detoxification of 1′-hydroxyestragole, mainly via 
conversion to 1′-oxoestragole, was similar within the two 
ethnic groups. The 4.5-fold variation in formation of the 
ultimate carcinogenic metabolite of estragole accompanied 
by similar rates of detoxification may indicate a lower risk 
of estragole for the Chinese population at similar levels of 
exposure. The study provides a proof of principle for how 
PBK modeling can identify differences in ethnic sensitivity 
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the predicted clearances for phenacetin, tolbutamide, desip-
ramine, omeprazole, alprazolam (intravenous), alprazolam 
(oral), midazolam (intravenous), and midazolam (oral) in 
Chinese subjects were predicted to be 36, 25, 43, 51, 21, 
22, 24, and 17% lower, respectively, than in Caucasian sub-
jects, and the experimentally observed clearances in treated 
Chinese individuals were 28, 2, 42, 75, 20, 21, 19, and 62% 
lower, respectively, than in Caucasian volunteers (Barter 
et al. 2013).
Thus, inter-ethnic differences in metabolism and meta-
bolic bioactivation and detoxification may occur. However, 
systematic attempts to predict the kinetic processes and 
related toxicity in different populations using physiologi-
cally based kinetic (PBK) modeling are lacking. The aim 
of the present study was to determine PBK modeling-based 
predictions for differences between Chinese and Cauca-
sians in terms of metabolic bioactivation and detoxification 
of the food-borne genotoxic carcinogen estragole (Fig. 1). 
Estragole (1-allyl-4-methoxybenzene) is an alkenylbenzene 
that is naturally present in a variety of herbs and spices, 
such as fennel, basil, and tarragon (Smith et al. 2002). Con-
sumption of herbs, spices, and their essential oils and food 
products containing these is an important route of exposure 
to estragole. The Flavor and Extract Manufacturers Associ-
ation (FEMA) estimated the daily intake of estragole to be 
less than 0.01 mg/kg bw/day based on the annual produc-
tion volume data of estragole for use in flavorings (Smith 
et  al. 2002). Estragole is known to be genotoxic and car-
cinogenic in rodents at high-dose levels (Drinkwater et al. 
1976; Miller et  al. 1983). Bioactivation of estragole to a 
DNA reactive ultimate carcinogen proceeds by cytochrome 
P450 mediated conversion to 1′-hydroxyestragole and 
subsequent conversion of 1′-hydroxyestragole to the ulti-
mate carcinogen 1′-sulfooxyestragole by sulfotransferases 
(SULTs) (Fig.  1). Detoxification of 1′-hydroxyestragole 
proceeds by glucuronidation to 1′-hydroxyestragole glucu-
ronide and oxidation to 1′-oxoestragole (Fig. 1). Given the 
variety of biotransformation enzymes involved in estragole 




bioactivation and detoxification, estragole was selected as 
an adequate model compound to study ethnic differences in 
bioactivation and detoxification. To define the PBK mod-
els for the Chinese and Caucasian populations, kinetic 
constants for the various biotransformation reactions of 
estragole were quantified using in  vitro incubations with 
relevant tissue fractions of the two ethnic groups. The out-
comes predicted by the PBK model for the Chinese popula-
tion were compared to those predicted by the PBK model 
for Caucasians to evaluate the inter-ethnic differences in 
metabolic activation and detoxification of estragole and to 




Estragole (1-allyl-4-methoxybenzene), dimethylsulfoxide 
(DMSO), alamethicin, uridine 5′-diphosphoglucuronic 
acid (UDPGA), 3′-phosphoadenosine-5′-phosphosulfate 
(PAPS), phenacetin, acetaminophen, coumarin, 7-hydroxy-
coumarin, 7-hydroxycoumarin sulfate, glucose-6-phos-
phate dehydrogenase, and reduced L-glutathione (GSH) 
were purchased from Sigma–Aldrich (Steinheim, Ger-
many). Potassium dihydrogen phosphate, dipotassium 
hydrogen phosphate trihydrate, hydrochloric acid (37%), 
trifluoroacetic acid (TFA), and magnesium chloride were 
purchased from VWR International (Darmstadt, Germany). 
Reduced nicotinamide adenine dinucleotide phosphate 
(NADPH), nicotinamide adenine dinucleotide phosphate 
nicotinamide  (NADP+), adenine dinucleotide  (NAD+), and 
glucose-6-phosphate were obtained from Roche Diagnos-
tics (Mannheim, Germany). Acetonitrile (UPLC/MS grade) 
was obtained from Biosolve BV (Valkenswaard, Neth-
erlands). 1′-Hydroxyestragole, 4-allylphenol, estragole-
2′,3′-oxide, 3′-hydroxyanethole, and 1′-oxoestragole were 
synthesized as previously described by Punt et  al. (2007, 
2008). Chinese liver microsomes and Chinese S9, made 
from 40 donors, were purchased from PrimeTox (Wuhan, 
China). Caucasian liver microsomes were purchased from 
BD Gentest (Woburn, MA, USA), and Caucasian liver S9 
was purchased from Corning (Amsterdam, Netherlands). 
All microsomes and S9 were of pooled mixed gender.
In vitro incubations
Assessment of metabolic capabilities of CYP and SULT 
enzymes in Chinese and Caucasian liver samples
The quality of the Chinese and Caucasian liver microsomes 
was checked by measuring the activity of CYP1A2 and 
CYP2A6 by the method of Yang et al. (2012). The quality 
of Chinese and Caucasian liver S9 samples was checked by 
measuring the SULT activity based on the method provided 
by Wang et al. (2006). The details of the methods for the 
microsomal and S9 in vitro incubations and UPLC analysis 
for assessing the metabolic capabilities of CYP and SULT 
enzymes can be found in the supporting materials 1.
Microsomal metabolism of estragole
The kinetic constants for the microsomal conversion of 
estragole were determined as previously described by Punt 
et al. (2009). Briefly, mixed gender Chinese or Caucasian 
liver microsomes were incubated with estragole in the pres-
ence of NADPH. The incubation mixtures contained (final 
concentrations) 3 mM NADPH and 1 mg/mL microsomal 
protein in 0.2 M Tris–HCl (pH 7.4). Incubations were per-
formed for 10 min at substrate concentrations ranging from 
25 to 1000  μM, after which the reaction was terminated 
by adding 25  μL ice-cold acetonitrile. Blank incubations 
were performed in the absence of the cofactor NADPH. All 
incubations were performed in triplicate. In the supporting 
materials 2, detailed information can be found (Table  S1 
can be used to keep track of detailed information).
Glucuronidation of 1′‑hydroxyestragole
Pooled mixed gender Chinese or Caucasian liver micro-
somes were incubated with 1′-hydroxyestragole in the 
presence of UDPGA. As previously described by Punt 
et al. (2009), the incubation mixtures contained (final con-
centrations) 10  mM UDPGA, and 1  mg/mL microsomal 
protein in 0.2  M Tris–HCl (pH 7.4) with 10  mM  MgCl2. 
Incubations were carried out for 6 h, and the reaction was 
terminated by adding 25  μL ice-cold acetonitrile. Blank 
incubations were performed in the absence of the cofac-
tor UDPGA. All incubations were performed in triplicate. 
In the supporting materials 2, detailed information can 
be found (Table  S1 can be used to keep track of detailed 
information).
Oxidation of 1′‑hydroxyestragole
Mixed gender Chinese or Caucasian liver S9 was incubated 
with 1′-hydroxyestragole in the presence of  NAD+ and 
GSH, the latter added to trap the transient 1′-oxoestragole. 
Formation of the 1′-oxoestragole adducts with GSH 
forming GS-1′-oxoestragole reflects the formation of 
1′-oxoestragole (Punt et  al. 2009). The incubations had a 
final volume of 100  μL, containing (final concentrations) 
3 mM  NAD+, 2 mM GSH, and 1 mg/mL liver S9 in 0.2 M 
Tris–HCl (pH 7.4), as described previously by Punt et  al. 
(2016). The reactions were terminated after 10 min by the 
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addition of 25 μL ice-cold acetonitrile. Blank incubations 
were performed without cofactor  NAD+. All incubations 
were performed in triplicate. In the supporting materials 2, 
detailed information can be found (Table S1 can be used to 
keep track of detailed information).
Sulfation of 1′‑hydroxyestragole
The formation of 1′-sulfooxyestragole was determined by 
incubating 0.2  mg/mL pooled mixed gender Chinese or 
Caucasian liver S9 in the presence of 0.2  mM PAPS as 
cofactor and 10  mM GSH as trapping agent for the reac-
tive 1′-sulfooxyestragole in 0.1 M potassium phosphate (pH 
8.0). The incubations were carried out for 2 h, and the reac-
tions were terminated by adding 25 μL ice-cold acetonitrile. 
The blank samples were performed without cofactor. All 
incubations were performed in triplicate. In the supporting 
materials 2, detailed information can be found (Table  S1 
can be used to keep track of detailed information).
UPLC analysis
UPLC analysis of estragole metabolites
Before UPLC analysis, all samples were centrifuged for 
5  min at 16,000  g to precipitate microsomal proteins. 
Supernatant of each sample was analyzed on UPLC using a 
BEH C18 (1.7 μm, 2.1 × 50 mm) column with a guard col-
umn and a diode array detector (Acquity, Waters). The gra-
dient for analysis of metabolites of estragole can be found 
in supporting materials 2. Table  S1 can be used to keep 
track of detailed information. Identification of microsomal 
metabolites of estragole, including 4-allylphenol, estragole-
2′,3′-diol, 1′-hydroxyestragole, and 3′-hydroxyanethole, 
and M5 was achieved by comparison of the UV spectra 
and retention times of formed metabolites to those of syn-
thesized reference compounds identified previously (Punt 
et  al. 2007, 2008). Formation of 4-allylphenol, estragole-
2′,3′-diol, and 1′-hydroxyestragole was quantified by com-
paring the peak areas to those of the corresponding refer-
ence standard curves at wavelength 225  nm (Agharahimi 
and LeBel 1995; Drinkwater et al. 1976; Iyer et al. 2003; 
Luo et al. 1992). Because the UV spectrum of M5 is simi-
lar to that of estragole-2′,3′-diol, quantification of M5 could 
be achieved by comparison of the peak area to the calibra-
tion curve of estragole-2′,3′-diol at 225  nm. 3′-Hydroxy-
anethole was quantified by comparison of the peak areas of 
the metabolite in the chromatograms obtained at a wave-
length of 206 nm to the calibration curve of the synthesized 
reference compound (Agharahimi and LeBel 1995; Drink-
water et  al. 1976; Iyer et  al. 2003; Luo et  al. 1992). The 
amounts of formed microsomal estragole metabolites were 
corrected for the amounts detected in the blank incubations 
performed without the respective cofactor NADPH.
UPLC analysis of 1′‑hydroxyestragole metabolites
Before UPLC analysis, all samples were centrifuged for 
5 min at 16, 000 g to precipitate microsomal or cytosolic 
proteins. Supernatant of each sample was analyzed on 
UPLC using a BEH C18 (1.7  μm, 2.1 × 50  mm) column 
with a guard column and a diode array detector (Acquity, 
Waters). Secondary metabolism of 1′-hydroxyestragole 
includes glucuronidation, oxidation, and sulfation. The gra-
dient of analysis of  the metabolites of 1′-hydroxyestragole 
can be found in supporting materials 2. Table  S1 can be 
used to track more detailed information.
Identification of 1′-hydroxyestragole glucuronide 
was achieved by the fact that it was the only metabolite 
formed and by LC-MS analysis as reported previously 
(Punt et  al. 2008). Both 1′-hydroxyestragole glucuronide 
and 1′-hydroxyestragole have the same UV spectrum and 
the same extinction coefficient at a wavelength of 225 nm. 
Thus, the quantification of 1′-hydroxyestragole glucuronide 
could be achieved by comparing the peak area to the cali-
bration curve of 1′-hydroxyestragole at wavelength 225 nm 
(Punt et al. 2009). The amounts of 1′-hydroxyestragole glu-
curonide formed were corrected for the amounts detected 
in the blank incubations performed without the respective 
cofactor UDPGA.
Identification of the GS-1′-oxoestragole which reflects 
the formation of 1′-oxoestragole was done by com-
paring the UV spectra and retention time of the formed 
GSH adduct to those of GS-1′-oxoestragole identified as 
described previously (Punt et  al. 2009). Quantification 
of the GSH conjugate of 1′-oxoestragole was achieved 
by comparing the peak area to the calibration curve of 
GS-1′-oxoestragole at a wavelength of 280 nm prepared as 
described previously by Punt et  al. (2009, 2016). Briefly, 
the calibration curve of GS-1′-oxoestragole was prepared 
by incubating 40 μM 1′-oxoestragole with a range of GSH 
concentrations. The reactions were incubated for 4 h after 
which maximal formation of GS-1′-oxoestragole was previ-
ously shown to be reached (Punt et al. 2009). The amounts 
of 1′-oxoestragole formed were corrected for the amounts 
detected in the blank incubations performed without the 
respective cofactor  NAD+.
Since the UV spectrum of 3′-hydroxyanethole is similar 
to that of the GSH adduct of 1′-sulfooxyestragole, quanti-
fication of 1′-sulfooxyestragole could be achieved by com-
paring the peak area of the GSH adduct of 1′-sulfooxy-
estragole to the calibration curve of 3′-hydroxyanethole 
at a wavelength 260  nm as described for the quantifica-
tion of 1′-sulfooxysafrole and 1′-sulfooxyelemicin (Mar-
tati et al. 2012; Van den Berg et al. 2012). The amount of 
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1′-sulfooxyestragole GSH adduct formed was corrected for 
the amount detected in the blank samples performed with-
out the respective cofactor PAPS.
Kinetic analysis
The data for the formation of estragole and 1′-hydroxy-
estragole metabolites with increasing substrate concen-
tration [S] were fitted to the standard Michaelis–Menten 
equation:
The apparent maximum velocity (Vmax) and the apparent 
Michaelis–Menten constant (Km) were determined by fit-
ting the data to this equation using GraphPad Prism version 
5.0 (GraphPad software, San Diego California USA).
PBK model structure
The PBK models developed in this study were based on 
the PBK models previously defined by Punt et al. (2008). 
The models have six compartments, including blood, fat, 
rapidly perfused tissue, slowly perfused tissue, liver, and 
GI tract that are mutually connected through the systemic 
circulation. A schematic diagram of the PBK models for 
estragole kinetics is presented in Fig.  2, and the code 
of the models can be found in the supporting materi-
als 6. Table  1 summarizes the physiological parameters 
for Caucasian and Chinese subjects, respectively, which 
were derived from the literature (Brown et  al. 1997; 
NHFPC 2007, 2014b). Based on the method described 
by DeJongh et al. (1997; Punt et al. 2016), partition coef-
ficients were estimated based on the log Kow. The log 
Kow values for estragole and 1′-hydroxyestragole were 
estimated by ChemBio 3D 2010 (CambrigeSoft, USA). 
Model equations were coded and numerically integrated 
휐 = Vmax∕(1 + (Km∕[S]).
in Berkely Madonna (Macey and Oster, UC Berkeley, 
CA, USA) using the Rosenbrock’s algorithm for stiff 
systems.
Estragole was assumed to directly enter from the gas-
trointestinal tract via the portal vein into the liver with 
Fig. 2  Schematic diagram of 
the PBK model for estragole in 
human, including the name of 
kinetic parameters for metabo-
lites of estragole and 1′-hydroxy-
estragole as used in the mass 
balance equations of the PBK 
model
Table 1  Parameters used in the physiologically based kinetic model 
for estragole in Chinese and Caucasian populations as obtained from 
the literature
a NHFPC (2007); NHFPC (2014b)
b Brown et al. (1997)
c DeJongh et al. (1997)
Model parameters Chinesea,c Caucasianb,c
Physiological parameters
 Body weight (kg) 60 70
Percentage of body weight
 Liver 2.3 2.6
 Fat 18.7 21.4
 Rapidly perfused 5.3 5
 Slowly perfused 54.3 51.7
 Blood 7.9 7.9
 Cardiac output (l/hr/kg  bw0.74) 15 15
Percentage of cardiac output
 Liver 26.3 22.7
 Fat 6.75 5.2
 Rapidly perfused 43.8 47.3
 Slowly perfused 23.3 24.8




  Rapidly perfused 6.5 6.5





an absorption rate constant (Ka) of 1.0 h−1 as a first-order 
process. This value was used based on the fact that com-
plete and fast absorption of estragole from the GI tract 
has been observed (Anthony et  al. 1987). As reported 
by Punt et  al. (2009), conversion of estragole mainly 
occurs in the liver and not in other organs. In addition, 
since the liver is known to be the major target organ for 
estragole-induced tumor formation in rat and mice, the 
PBK model focused on metabolism of estragole and 
1′-hydroxyestragole in the liver. 1′-Hydroxyestragole, 
2′,3′-estragole oxide, 3′-hydroxyanethole, 4-allylphenol, 
and an unidentified minor metabolite referred to as M5 
were formed in incubations with liver microsomes from 
both populations (see “Results” section), and conver-
sions of estragole into these metabolites were included 
in the liver compartment of the models. In both models, 
descriptions of the conversions of 1′-hydroxyestragole 
into its further metabolites were included, but the con-
versions of 2′,3′-estragole oxide, 3′-hydroxyanethole, 
4-allylphenol, and M5 to their further metabolites were 
not included, since these are assumed to not influence the 
formation of the ultimate carcinogenic metabolite 1′-sul-
fooxyestragole. The mass balance equations for microso-
mal conversion of estragole when using Chinese or Cau-
casian liver microsomes were described as follows:
where  ALE is the amount of estragole in the liver tissue 
(μmol).  UptakeE is the amount of estragole taken up from 
the GI tract (μmol), QL is the blood flow rate to and from 
the liver tissue (L/h),  CAE is the estragole concentration in 
the arterial blood (μmol/L), and  CLE is the estragole con-
centration in the liver tissue.  PLE is the liver/blood parti-
tion coefficient, Vmax, L_M and Km, L_M are the maximum 
rate of formation and Michaelis–Menten constant for the 
metabolites 4-allylphenol (AP), 1′-hydroxyestragole (HE), 
estragole-2′,3′-oxide (EE), 3′-hydroxyanethole (HA) and 
metabolite 5 (M5) in the liver tissue,  AGIE (μmol) is the 
amount of estragole in the GI tract, and VL is the volume 
of the liver. The mass balance equation for the metabolism 
of 1′-hydroxyestragole in the liver was as follows:
dALE∕dt = dUptakeE∕dt
+ QL × (CAE − CLE∕PLE)
− Vmax , L_AP × (CLE∕PLE)∕(Km, L_AP + CLE∕PLE)
− Vmax , L_HE × (CLE∕PLE)∕(Km, L_HE + CLE∕PLE)
− Vmax , L_EE × (CLE∕PLE)∕(Km, L_EE + CLE∕PLE)
−Vmax , L_HA × (CLE∕PLE)∕(Km, L_HA + CLE∕PLE)
−Vmax , L_M5 × (CLE∕PLE)∕(Km, L_M5 + CLE∕PLE)
dUptakeE∕dt = − dAGIE∕dt = Ka × AGIE, AGIE(0) = oral dose
CLE = ALE∕VL
where  ALHE is the amount of 1′-hydroxyestragole in the 
liver tissue (μmol),  CLHE is the 1′-hydroxyestragole concen-
tration in the liver tissue (μmol/L),  PLHE is the liver/blood 
partition coefficient of 1′-hydroxyestragole, Vmax, L_M, and 
Km, L_M are the maximum rate and the Michaelis–Menten 
constant for the formation of 1′-hydroxyestragole glucuro-
nide (HEG), 1′-oxoestragole (OE) and 1′-sulfooxyestragole 
(HES) in the liver tissue.
The kinetic constants for metabolites formed were 
determined in  vitro in the present study. Vmax values 
expressed as nmol/min/(mg microsomal or S9 pro-
tein) were scaled to the Vmax per μmol/h/(g liver) using 
mirosomal and S9 protein yields of 35 and 143  mg/g 
liver, respectively, as previously described by Punt et al. 
(2009), Al-Subeihi et  al. (2012), Martati et  al. (2012), 
and Van den Berg et  al. (2012). Currently, no data are 
available specifically for the liver microsomal and S9 
protein relevant for the Chinese tissue samples. There-
fore, the value of liver microsomal protein and liver S9 
protein available for the Caucasians was used for the Chi-
nese population.
Sensitivity analysis
To identify which parameters have the greatest impact 
on the model predictions on the formation of 1′-hydrox-
yestragole and 1′-sulfooxyestragole, a sensitivity analysis 
was performed. Normalized sensitivity coefficients (SC) 
were determined using the following equation:
where C is the initial value of the model output; C′ is the 
modified model output resulting from a 5% increase of the 
parameter value; P is the initial parameter value; and P′ is 
the modified parameter value (Evans and Andersen 2000). 
A 5% increase in parameter values was chosen to analyze 
the effect of a change in parameter values on formation 
of 1′-hydroxyestragole and 1′-sulfooxyestragole at a dose 
0.01, 5, and 150  mg/kg bw/day for 24  h exposure, repre-
senting respectively a realistic daily intake (Smith et  al. 
2002), an intake that may result from supplement use (Van 
Den Berg et al. 2011) and a dose level known to cause liver 
tumors in rodent bioassays (Drinkwater et al. 1976; Miller 
et  al. 1983). Each parameter was analyzed individually, 
while other parameters were kept as their initial value.
dALHE∕dt = Vmax, L_HE × (CLE∕PLE)∕(Km, L_HE + CLE∕PLE)
− Vmax , L_HEG × (CLHE/PLHE)∕(Km, L_HEG + CLHE/PLHE)
− Vmax , L_OE × (CLHE/PLHE)∕(Km, L_OE + CLHE/PLHE)













Comparison of the PBK model-based predictions 
for bioactivation and detoxification of estragole 
in the Chinese and Caucasian population
The PBK model-based predictions for the formation of 
metabolites of estragole and 1′-hydroxyestragole in the 
Chinese population were compared with the predicted for-
mation of these metabolites in the Caucasian population. 
Model predictions were made for a period of 24  h after 
exposure.
Results
Metabolic capabilities of CYP and SULT enzymes
The results of metabolic capabilities of CYP and SULT 
enzymes can be found in supporting materials 3. The qual-
ity of the Chinese tissue samples used to determine the var-
ious kinetic parameters appeared to be in line with what has 
been reported before (Yang et al. 2012; Wang et al. 2006).
Microsomal conversion of estragole
The microsomal conversion of estragole was determined 
by incubating estragole with Chinese or Caucasian liver 
microsomes in the presence of NADPH. Figure S1 in sup-
porting materials 4 presents a representative chromatogram 
of an incubation with Chinese liver microsomes show-
ing the formation of estragole-2′,3′-diol (Rt = 2.9  min), 
1′-hydroxyestragole (Rt = 4.7  min), 3′-hydroxyane-
thole (Rt = 4.9  min), M5 (Rt = 5  min) and 4-allylphenol 
(Rt = 6.8  min). Since the metabolite referred to as M5 
was only formed in a relatively small amount in incuba-
tions with liver microsomes from both ethnic groups, its 
identification was not deemed essential. Due to the pres-
ence of epoxide hydrolase in the human liver microsomes, 
the formation of estragole-2′,3′-diol reflects formation of 
estragole-2′,3′-oxide (Guenthner and Luo 2001; Luo and 
Guenthner 1996; Luo et al. 1992).
The estragole concentration-dependent rates of for-
mation of estragole-2′,3′-oxide, 1′-hydroxyestragole, 
3′-hydroxyanethole, M5, and 4-allylphenol by Chinese or 
Caucasian liver microsomes is shown in Fig. 3. The kinetic 
constants for these metabolic conversions of estragole and 
the catalytic efficiency, calculated as Vmax/Km, obtained 
from these data are summarized in Table 2.
The results showed that estragole-2′,3′-oxide was the 
most abundant metabolite formed in incubations with liver 
microsomes from both populations, followed by 1′-hydrox-
yestragole. Analysis of catalytic efficiencies for the forma-
tion of the microsomal estragole metabolites revealed that 
the catalytic efficiency for formation of 1′-hydroxyestragole 
was the highest, followed by the formation of estragole-
2′,3′-oxide, 4-allylphenol, 3′-hydroxyanethole and M5 in 
both populations. Thus, formation of 1′-hydroxyestragole 
was the major microsomal metabolic pathway of estragole, 
whereas formation of M5 was the least important route of 
estragole metabolism. The catalytic efficiency for the for-
mation of 1′-hydroxyestragole was higher than that for the 
other microsomal metabolites because of a relatively low 
Km. Comparison of the catalytic efficiencies obtained for 
the two ethnic groups revealed that the catalytic efficiencies 
for the formation of 4-allylphenol, estragole-2′,3′-oxide, 
1′-hydroxyestragole, 3′-hydroxyanethole, and M5 in incu-
bations with the Chinese samples were 1.8-, 4.9-, 2.4-, 3.2-, 
and 2.9-fold lower, respectively, than those in incubations 
with Caucasian samples. The relatively low catalytic effi-
ciencies for the Chinese samples were mainly due to rela-
tively low Vmax values, which were 5.0-, 4.4-, 3.4-, 3.1-, and 
6.5-fold lower than the Vmax for O-demethylation, epoxida-
tion, 1′-hydroxylation, 3′-hydroxylation, and the reaction 
for the formation of M5 in Caucasian samples, respectively. 
The apparent Km values for these reactions by Chinese and 
Caucasian samples were similar.
Fig. 3  Concentration-depen-
dent rate of metabolic conver-
sion of estragole in incubations 
with Chinese (a) or Caucasian 
(b) liver microsomes. Data 
points represent mean val-
ues ± SEM of three individual 
experiments for each metabo-
lite, including estragole-2′,3′-
oxide (closed upward triangle), 
1′-hydroxyestragole (closed 
circle), 3′-hydroxyanethole 
(closed square), 4-allylphenol 
(closed downward triangle), and 
M5 (closed diamond)
Chinese












































































Kinetic constants for the formation of 1′-hydroxy-
estragole glucuronide were determined by incubations 
with Chinese or Caucasian liver microsomes in the pres-
ence of UDPGA and 1′-hydroxyestragole. 1′-Hydroxy-
estragole glucuronide eluted at 2.6  min and was identi-
fied by LC-MS as previously described (Punt et al. 2008). 
The metabolite was quantified using the calibration curve 
of 1′-hydroxyestragole on the basis of the similarity in 
their UV spectra assuming a similar molar extinction 
coefficient.
Figure 4a shows the 1′-hydroxyestragole concentration-
dependent rate of formation of 1′-hydroxyestragole glucu-
ronide by liver microsomes and kinetic constants derived 
from these plots are displayed in Table 2. The apparent Km 
and Vmax for formation of 1′-hydroxyestragole glucuronide 
by Chinese samples were 4656 µM and 1.63 nmol/min/(mg 
microsomal protein), respectively, whereas Km and Vmax for 
formation of 1′-hydroxyestragole glucuronide by Caucasian 
samples were 4607  µM and 4.29  nmol/min/(mg microso-
mal protein), respectively. These values result in a catalytic 
efficiency that is 2.7-fold lower for Chinese than for Cauca-
sian subjects.
Oxidation of 1′-hydroxyestragole
1′-Oxoestragole was formed in incubations with 
1′-hydroxy estragole and Chinese or Caucasian liver S9 
using  NAD+ as cofactor and GSH to trap 1′-oxoestragole 
forming GS-1′-oxoestragole. Chromatographic analysis 
revealed that GS-1′-oxoestragole eluted at 2.6 min based on 
its previous identification (Punt et al. 2009).
The rate of oxidation of 1′-hydroxyestragole with 
increasing concentration of 1′-hydroxyestragole is shown 
in Fig.  4b and Table  2 displays the kinetic constants for 
formation of 1′-oxoestragole derived from these data. The 
apparent Km for formation of 1′-oxoestragole by Chinese 
samples was 403 µM, and the Vmax was 1.82 nmol/min/(mg 
S9 protein). For Caucasian samples, the apparent Km and 
the Vmax were 521 µM and 2.8 nmol/min/(mg S9 protein), 
respectively. The catalytic efficiencies for formation of 
1′-oxoestragole by both ethnic groups were similar.
Sulfation of 1′-hydroxyestragole
Formation of the ultimate carcinogenic metabolite 1′-sul-
fooxyestragole upon sulfation of 1′-hydroxyestragole was 
observed in incubations with Chinese as well as Cauca-
sian liver S9 in the presence of PAPS and GSH. GSH was 
used to trap the transient 1′-sulfooxyestragole forming the 
GSH adduct of 1′-sulfooxyestragole. Chromatographic 
analysis revealed a peak at 1.4 min, identified as the GSH 
Table 2  Kinetic constants (average ± SEM) for metabolic conversion of estragole and 1′-hydroxyestragole in incubations with Chinese or Cau-
casian liver tissue fractions
a Vmax/Km × 1000
Ethnic group Chinese Caucasian
Metabolite Km (µM) Vmax (nmol /min/





mal or S9 protein)
Km (µM) Vmax (nmol /min/
mg microsomal or 
S9 protein)
Catalytic  efficiencya 
(µL/min/mg micro-
somal or S9 protein)
Conversion of estragole
 4-Allylphenol 115 ± 24 0.15 ± 0.01 1.3 308 ± 71 0.74 ± 0.07 2.4
 Estragole-2′,3′-
oxide
161 ± 17 0.42 ± 0.01 2.6 146 ± 15 1.85 ± 0.06 12.7
 1′-Hydroxy-
estragole
49 ± 8 0.35 ± 0.01 7.9 62 ± 9 1.19 ± 0.04 19.3
 3′-Hydroxyane-
thole
450 ± 219 0.32 ± 0.07 0.71 429 ± 80 0.99 ± 0.08 2.3





4656 ± 1247 1.63 ± 0.33 0.35 4607 ± 878 4.29 ± 0.61 0.93
 1′-Oxoestragole 403 ± 137 1.82 ± 0.28 4.5 521 ± 265 2.8 ± 0.70 5.4
 1′-Sulfooxy-
estragole
694 ± 321 0.0014 ± 0.0002 0.0021 423 ± 159 0.004 ± 0.0005 0.01
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adduct of 1′-sulfooxyestragole. This identification was 
based on the fact that the peak was absent in the incuba-
tions with PAPS and S9 in the absence of GSH (chroma-
togram not shown), and the previous identification of this 
(Punt et al. 2007) and similar alkenylbenzene 1′-sulfooxy 
adducts by LC-MS (Al-Malahmeh et al. 2017; Al-Subeihi 
et al. 2012; Alajlouni et al. 2016; Martati et al. 2012).
Figure 4c presents the 1′-hydroxyestragole concentra-
tion-dependent rate of formation of 1′-sulfooxyestragole 
in incubations with Chinese or Caucasian liver S9 as 
determined by quantification of the GSH adduct of 1′-sul-
fooxyestragole. Table 2 presents a summary of the kinetic 
constants for formation of 1′-sulfooxyestragole in the two 
ethnic groups derived from these data. The catalytic effi-
ciency for formation of 1′-sulfooxyestragole in incubation 
with Chinese samples was fivefold lower than those in 
incubations with Caucasian samples.
Comparison of the kinetic constants for conversion 
of estragole and 1′-hydroxyestragole by Chinese 
and Caucasian liver tissue fractions
Table 3 displays the scaled kinetic parameters for conver-
sion of estragole and 1′-hydroxyestragole by Chinese or 
Caucasian liver tissue fractions. In this table, Vmax val-
ues that were obtained in  vitro expressed as nmol/min/
(mg microsomal protein or S9) (Table 2) were scaled to 
whole liver and expressed in µmol/h/(g tissue). A scaled 
catalytic efficiency (Vmax in vivo/Km) for formation of the 
different metabolites of estragole and 1′-hydroxyestragole 
could be calculated. The catalytic efficiencies thus 
obtained reveal that formation of the proximate carcino-
genic metabolite of estragole, 1′-hydroxyestragole, was 
2.5-fold lower for Chinese liver microsomes as compared 
to Caucasian liver micorosomes. This difference in cata-
lytic efficiency was mainly due to the low Vmax in Chinese 
Fig. 4  Concentration-depen-
dent rate of metabolic conver-
sion of 1′-hydroxyestragole to 
(a) 1′-hydroxyestragole glu-
curonide, (b) 1′-oxoestragole, 
and (c) 1′-sulfooxyestragole in 
incubations with Chinese or 
Caucasian liver tissue fractions. 
Data points represent mean val-
ues ± SEM of three individual 
experiments for each metabolite
 Chinese


















































































































































































































liver microsomes, since the value of Vmax in Chinese liver 
incubations was 3.5-fold lower than in Caucasian liver 
incubations. Epoxidation of estragole turned out to be 
the main route of microsomal metabolism of estragole in 
both ethnic groups, although the catalytic efficiency for 
formation of estragole-2′,3′-oxide was fivefold lower for 
the Chinese population. This lower catalytic efficiency 
was mainly due to a fourfold lower Vmax for Chinese liver 
samples.
Regarding the metabolic reactions of 1′-hydroxy-
estragole, formation of 1′-oxoestragole was the main 
detoxification pathway for this proximate carcinogenic 
metabolite in both populations. The catalytic efficiencies 
for formation of 1′-oxoestragole in both populations were 
similar. However, the  catalytic efficiency for formation 
1′-hydroxyestragole glucuronide, another detoxification 
route of 1′-hydroxyestragole was found to be threefold 
lower in incubations with Chinese than with Cauca-
sian liver microsomes, resulting from a threefold lower 
Vmax. Sulfation of 1′-hydroxyestragole in both popula-
tions, reflecting bioactivation to a reactive ultimate car-
cinogen, was found to be the least efficient pathway for 
1′-hydroxyestragole metabolism for both ethnic groups. 
For Chinese samples, the scaled catalytic efficiency for 
this bioactivation reaction was 4.5-fold lower than for the 
Caucasian samples.
Comparison of the PBK model-based predictions 
for bioactivation and detoxification of estragole 
in Chinese and Caucasians
Comparison of the overall consequences of the observed 
differences in kinetic constants for all the individual bio-
activation and detoxification reactions of estragole between 
the two ethnic groups requires integration of all data in a 
PBK model. In the present study, these PBK models were 
defined based on the PBK model for estragole in human 
previously developed (Punt et al. 2009), using the popula-
tion specific physiological and kinetic parameters defined 
in the present study. The PBK model for estragole for Cau-
casians was evaluated previously by comparing the pre-
dicted formation of 4-allylphenol and 1′-hydroxyestragole 
glucuronide to the observed dose levels of these metabo-
lites in  vivo (Punt et  al. 2009). The performance of the 
PBK model for estragole for the Chinese population could 
not be evaluated against Chinese in  vivo data because 
quantitative data on the excretion of different metabolites 
of estragole in Chinese subjects after oral exposure to 
estragole are not available. Evaluation of the model could 
only be made by comparing the predicted inter-ethnic dif-
ferences in formation of 1′-hydroxyestragole to reported 
ethnic differences in hepatic drug-metabolizing enzymes 
that mainly catalyze the formation of metabolites of 
Table 3  Scaled kinetic constants (average ± SEM) for metabolic conversion of estragole and 1′-hydroxyestragole from incubations with Chinese 
or Caucasian liver tissue fractions
a Scaled Vmax in vivo expressed as µmol/h/(g liver), calculated from the in vitro Vmax based on a microsomal protein yield of 35 mg/(g tissue) and 
an S9 protein yield of 143 mg/(g tissue)
b Catalytic efficiency expressed as µL/h/(g liver) is the ratio of scaled Vmax and Km
Ethnic Chinese Caucasian
Metabolite Km (µM) Scaled Vmaxa 
(µmol/h/g liver)
Catalytic 
 efficiencyb (µL/h/g 
liver)
Km (µM) Scaled Vmaxa 
(µmol/h/g liver)
Catalytic  efficiencyb 
(µL/h/g liver)
Conversion of estragole
 4-Allylphenol 115 ± 24 0.3 2.7 308 ± 71 1.6 5.0
 Estragole-2′,3′-
oxide
161 ± 17 0.9 5.5 146 ± 15 3.9 26.6
 1′-Hydroxy-
estragole
49 ± 8 0.7 15.0 62 ± 9 2.5 40.3
 3′-Hydroxyane-
thole
450 ± 219 0.7 1.5 429 ± 80 2.1 4.8





4656 ± 1247 3.4 0.7 4607 ± 878 9.0 2.0
 1′-Oxoestragole 403 ± 137 15.6 38.7 521 ± 265 24.0 46.1
 1′-Sulfooxy-
estragole
694 ± 321 0.01 0.02 423 ± 159 0.03 0.08
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estragole to 1′-hydroxyestragole. CYP1A2 and CYP2A6 
predominantly catalyze formation of 1′-hydroxyestragole 
with CYP2C19, CYP2D6, and CYP2E1 contributing to 
some extent at high concentrations of estragole (Jeurissen 
et  al. 2007). The PBK model-based predicted formation 
of 1′-hydroxyestragole at an oral dose of 0.01 mg/kg bw, a 
realistic dietary intake level (Smith et al. 2002), in Chinese 
liver, amounted to 43% of the dose, which was similar to 
the relative amount of 1′-hydroxyestragole predicted to be 
formed in the Caucasian liver, which was 47% of the dose 
as shown in Fig. 6. Although the catalytic efficiency in for-
mation of 1′-hydroxyestragole in Chinese subjects is two to 
threefold lower than that of those in Caucasian incubations, 
the predicted overall formation of 1′-hydroxyestragole over 
24 h in both ethnic groups is similar. Therefore, although 
the catalytic efficiency for estragole 1′-hydroxylation in 
the Chinese subjects is lower, when considering a time for 
conversion of 24 h the overall % of the dose converted to 
1′-hydroxyestragole still appears to be similar. The predic-
tion of similar overall formation of 1′-hydroxyestragole in 
both ethnic groups is in line with the experimental obser-
vation that peak plasma concentrations achieved at 0.5–2 h 
and apparent oral clearance values within 7 h of administra-
tion for phenacetin, a marker for CYP1A2 activity, did also 
not differ between Chinese and Caucasian subjects (Bar-
toli et al. 1996). At a high-dose level of 300 mg/kg bw/day 
estragole, the predicted formation of 1′-hydroxyestragole in 
the liver of Chinese subjects was twofold lower (13 versus 
25% of the dose) than the predicted formation in the liver 
of Caucasian subjects. This would be in line with the fact 
that at higher estragole concentrations, CYP2C19 might 
become involved in estragole 1′-hydroxylation and the fact 
that the frequency of poor metabolizers (PM) for CYP2C19 
in the Chinese populations was 14.6% compared to 3.3% in 
a Swedish population (Bertilsson et  al. 1992). Altogether, 
the PBK models obtained were considered adequate for 
further predictions of inter-ethnic differences in estragole 
metabolism, also because of the previous evaluation of the 
model for human as reported in the literature (Punt et  al. 
2009).
Figure  5 shows the PBK model-based predictions for 
the time-dependent formation of 1′-hydroxyestragole and 
1′-hydroxyestragole metabolites in both ethnic groups at a 
dose level of 0.01 mg/kg bw/day of estragole. Although the 
catalytic efficiency in formation of 1′-hydroxyestragole in 
incubations with liver samples from Chinese subjects is two 
to threefold lower than that in incubations with Caucasian 
samples, the predicted Cmax and 24 h AUC of 1′-hydroxy-
estragole in both the groups are similar. The predicted for-
mation of the different metabolites amounted to 0.02 nmol/
(g liver) for 1′-hydroxyestragole glucuronide, 1.2  nmol/
(g liver) for 1′-oxoestragole and 0.0005 nmol/(g liver) for 
1′-sulfooxyestragole in Chinese subjects, corresponding 
to 0.8, 42, and 0.02% of the dose, respectively (Fig.  5). 
For the Caucasians, these values amounted to 0.05  nmol/
(g liver) for 1′-hydroxyestragole glucuronide, 1.2  nmol/
(g liver) for 1′-oxoestragole and 0.002  nmol/(g liver) for 
1′-sulfooxyestragole, corresponding to 2, 45 and 0.09% of 
the dose, respectively (Fig. 5).
Figure 6 presents the PBK model-based predictions for 
the dose-dependent formation of 1′-hydroxyestragole and 
metabolites of 1′-hydroxyestragole in both ethnic groups. 
Differences on predicted formation of the various estragole 
metabolites in both ethnic groups can be considered fol-
lowing estragole exposure at 0.01, 5, and 150  mg/kg bw/
day, representing, respectively, a realistic daily intake 
(Smith et  al. 2002), an intake that may result from sup-
plement use (Van Den Berg et  al. 2011) and a dose level 
known to cause liver tumors in rodent bioassays (Drink-
water et al. 1976; Miller et al. 1983). Figure 6 shows that 
the ethnic differences in predicted formation of estragole 
metabolites in both ethnic groups at a dose of 0.01 mg/kg 
bw/day are similar to the situation for these metabolites 
formed in both ethnic groups at a dose of 5 mg/kg bw/day 
estragole. When the dose level increases up to 150 mg/kg 
bw/day, the ethnic difference in predicted metabolites of 
estragole increases. Figure 6a displays the predicted forma-
tion of 1′-hydroxyestragole in both ethnic groups. At dose 
level of 0.01 mg/kg bw/day of estragole, no ethnic differ-
ence in the formation of 1′-hydroxyestragole is observed. 
When the dose level increases up to 150  mg/kg bw/day, 
the relative formation of 1′-hydroxyestragole in both ethnic 
subjects decreased due to the saturation of this metabolic 
route. However, the formation of 1′-hydroxyestragole pre-
dicted for Chinese liver was 1.5-fold lower than for Cau-
casian liver. At relatively high concentrations of estragole, 
CYP2C19 might start to be involved in 1′-hydroxyestragole 
formation and a genetic polymorphism between Chinese 
and Caucasians has been reported with higher frequency 
of slow metabolizers in the Chinese population (Bertils-
son et  al. 1992) which may provide an explanation for 
the observed effect. Figure  6b presents the predicted for-
mation of 1′-oxoestragole in both ethnic groups. Oxida-
tion of 1′-hydroxyestragole represents the main metabolic 
route for 1′-hydroxyestragole in both ethnic groups at all 
three dose levels of estragole. The predicted formation 
of 1′-oxoestragole was similar at 0.01  mg/kg bw/day of 
estragole, 41.2% of the dose for Chinese, and 45% of the 
dose for Caucasians. At 5 mg/kg bw/day of estragole, 39% 
of dose was converted to 1′-oxoestragole in Chinese and 
44% of the dose in Caucasians. When a dose of 150 mg/
kg bw/day estragole was applied, only 19% of the dose 
was converted to 1′-oxoestragole for Chinese and 28% 
for Caucasians. The ethnic difference in formation of this 
metabolite was increased from onefold at 0.01 mg/kg bw/
day to 1.5-fold at 150  mg/kg bw/day estragole. Figure 6c 
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shows that the PBK model-based predicted formation 
of 1′-hydroxyestragole glucuronide in the Chinese liver 
was 2.4-fold lower than the levels predicted to be formed 
in Caucasians at a dose level of 0.01  mg/kg bw/day of 
estragole. At a dose level of 5 mg/kg bw/day of estragole, 
there was a 2.6-fold difference in formation of 1′-hydroxy-
estragole glucuronide between the ethnic subjects, and at a 
dose level of 150 mg/kg bw/day of estragole, the difference 
increased to 3.4-fold. Figure  6d reveals that the PBK 
model-based predicted formation of 1′-sulfooxestragole 
was 4.5-fold lower for Chinese than Caucasian liver at 
0.01  mg/kg bw/day of estragole. The ethnic difference in 
formation of 1′-sulfooxyestragole was 5.1-fold at 5  mg/
kg bw/day and 6.6-fold at 150 mg/kg bw/day of estragole 
pointing at lower levels of bioactivation to the ultimate car-
cinogenic metabolite for the Chinese population.
Fig. 5  PBK model-based 
predictions for the time-
dependent concentration of 
1′-hydroxyestragole in liver 
(a), and overall formation of 
1′-oxoestragole (b), 1′-hydroxy-
estragole glucuronide (c), and 
1′-sulfooxyestragole (d) in 
Chinese (dashed line) and Cau-
casian (continuous line) liver 
















































































Fig. 6  PBK model-based pre-
dictions for the dose-dependent 
formation of (a) 1′-hydroxy-
estragole, (b) 1′-oxoestragole, 
(c) 1′-hydroxyestragole glu-
curonide, and (d) 1′-sulfooxy-
estragole in Chinese (dashed 
line) and Caucasian (continuous 
line) liver




































































































































A sensitivity analysis was performed to determine model 
parameters that are able to influence the formation of 
1′-hydroxyestragole and 1′-sulfooxyestragole in both ethnic 
groups to the largest extent. Sensitivity coefficients were 
calculated for all model parameters at a dose of 0.01, 5, and 
150 mg/kg bw/day estragole, but only the parameters that 
appeared to have a sensitivity coefficient higher than |0.1| 
are presented in Fig. S2 in supporting materials 5.
In Chinese and Caucasian liver at 0.01  mg/kg bw of 
estragole (Fig. S2a), formation of 1′-hydroxyestragole 
is predominantly influenced by the kinetic constant for 
1′-hydroxylation, and to a minor extent by the kinetic con-
stants for formation of estragole-2′,3′-oxide. Focusing on 
inter-ethnic differences, it can be concluded that param-
eters, including liver volume, blood flow to fat and micro-
some protein yield of liver, have higher effect on the for-
mation of 1′-hydroxyestragole in Chinese liver compared 
to Caucasian liver. Formation of 1′-sulfooxyestragole 
mainly depends on the kinetic constants for its formation 
from 1′-hydroxyestragole, the formation of 1′-hydroxy-
estragole itself, and the kinetic constants for formation of 
1′-oxoestragole, which is an important competing meta-
bolic pathway to sulfation in both ethnic groups. At 5 mg/
kg bw/day of estragole (Fig. S2b), the results of the sen-
sitivity analysis of both ethnic groups are similar to the 
situation at a dose of 0.01 mg/kg bw/day. When the dose 
increases to 150  mg/kg bw/day (Fig. S2c), besides the 
influential parameters at a dose of 0.01 and 5  mg/kg bw/
day of estragole, the parameters related to fat tissue, such 
as volume of fat and  fat/blood partition coefficient, also 
have influence on the formation of 1′-hydroxyestragole and 
1′-sulfooxyestragole in Chinese liver. For the Caucasian 
group, the results of the sensitivity analysis at 150 mg/kg 
bw/day are similar to those at 0.01 or 5 mg/kg bw/day of 
estragole.
Discussion
In the present study, bioactivation and detoxification of 
estragole in Chinese and Caucasian populations upon oral 
exposure to estragole were examined using PBK mod-
eling. The structure of the PBK models was based on the 
model developed and validated previously for estragole in 
Caucasians (Punt et al. 2009). The parameter values for the 
Chinese PBK model were derived from literature or from 
incubation experiments using human liver fractions. To 
guarantee adequate experimental comparison, the param-
eters for hepatic metabolism in the Caucasian model were 
redefined in the present study as well. The kinetic constants 
of estragole metabolism obtained from incubation with 
Caucasian liver fractions and PBK model predictions of 
estragole in Caucasians in this study were similar to results 
reported in the study by Punt et al. (2009).
Since the actual kinetic data on plasma or urinary 
estragole metabolite levels were not available for the Chi-
nese population, the performance of the model was evalu-
ated by comparing the predicted inter-ethnic differences in 
formation of 1′-hydroxyestragole to reported ethnic differ-
ences in hepatic drug-metabolizing enzymes CYP1A2 that 
mainly catalyze the formation of metabolites of estragole to 
1′-hydroxyestragole. Furthermore, the PBK model for the 
Chinese population was based on the model for estragole 
defined and validated previously (Punt et  al. 2009). In 
addition, the quality of the Chinese tissue samples used to 
determine the various kinetic parameters appeared to be in 
line with what has been reported before (Yang et al. 2012; 
Wang et al. 2006). Considering these facts, it can be con-
cluded that the developed PBK model for the Chinese pop-
ulation is expected to adequately describe the in vivo levels 
of metabolites upon oral exposure.
The ethnic difference in bioactivation of estragole was 
evaluated by predicting the formation of 1′-sulfooxy-
estragole at doses level of 0.01 and 5  mg/kg bw/day of 
estragole. The PBK models predicted that following an 
exposure of 0.01  mg/kg bw/day estragole, only 0.02% of 
the estragole dose was predicted to be converted to 1′-sul-
fooxyestragole in the Chinese population, whereas 0.09% 
of the dose was converted to 1′-sulfooxyestragole in Cau-
casians, which was 4.5-fold higher. At 5 mg/kg bw/day of 
estragole, a worst case scenario intake for people using 
plant food supplements containing estragole (Van Den 
Berg et  al. 2011), the difference in the predicted forma-
tion of 1′-sulfooxyestragole between the two ethnic groups 
was increased to fivefold. This four to fivefold difference in 
the level of bioactivation of estragole between the two eth-
nic groups mainly originates from the difference in SULT 
mediated conversion of 1′-hydroxyestragole. The human 
SULTs involved in this sulfation reaction have not been 
identified to date, but sulfation of the 1′-hydroxy metabo-
lite of the related alkenylbenzene methyleugenol in the 
liver has been shown to be catalyzed mainly by SULT1A1 
and to a small extent by SULT1E1 (Herrmann et al. 2012). 
It has also been shown that exon 7 of the SULT1A1 gene 
may contain a G to A transition at codon 213 (rs9282861), 
which induces an Arg to His amino acid substitution 
(Raftogianis et  al. 1997). This SULT1A1 Arg213His 
(rs9282861) polymorphism is reported to be associated 
with increased risk of various cancer types (Xiao et  al. 
2014). In the ethnic subgroup analysis of Xiao et al., they 
found that the genotype distributions of the SNP site are 
different for different ethnic groups. Occurrence of the His 
allele in Asians (9.58%) was reported to be significantly 
lower than in Caucasians (35.2%). This difference of the 
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His allele frequency could contribute to differential drug 
responses between these two ethnic groups. It is tempting 
to speculate that the SNP difference in SULT1A1 between 
the ethnic groups may explain the differences in formation 
of 1′-sulfooxyestragole as observed in the present study, 
although a definite conclusion should await measurement 
of the respective SULT reaction using samples from indi-
viduals from both genotypes.
It is of interest to consider the possible consequences 
of the ethnic variation in bioactivation of estragole 
for the related health risks. Among the different avail-
able qualitative and quantitative approaches for making 
such a risk assessment for a genotoxic and carcinogenic 
compounds, the use of the Margin of exposure (MOE) 
approach was advised by EFSA (EFSA 2005). The MOE 
is a dimensionless value that is the ratio of a reference 
point derived from experimental data on tumor inci-
dence and the estimated daily intake of human. Gener-
ally, the  BMDL10 which is the lower confidence bound 
of the Benchmark Dose that gives 10% extra cancer inci-
dence above background levels can be used as the point 
of departure (Barlow et  al. 2006). Using an estimated 
daily intake of 0.01  mg/kg bw/day and the  BMDL10 of 
3.3–6.5 mg/kg bw/day for estragole (Van Den Berg et al. 
2011), the MOE value would amount to 330 up to 650, 
which is lower than 10,000, suggesting a priority for risk 
management. In Europe since 2008 the use of estragole 
as pure flavoring substance in foodstuffs has been pro-
hibited, and for a few food categories, maximum levels 
of naturally occurring estragole in foodstuffs have been 
defined (EC 2008). When estimated daily intakes would 
amount to 5 mg/kg/day, for example, as a result of daily 
use of estragole-containing plant food supplements 
(Van Den Berg et al. 2011), then the MOE values would 
amount to 0.66 up to 1.3, indicating that the daily intake 
of estragole using plant food supplements is within the 
range of the dose levels causing tumors in the experimen-
tal animals. Considering the consequences of five-fold 
reduction in bioactivation of estragole at similar dose lev-
els in the Chinese as compared to the Caucasian popula-
tion, as predicted by the results of the present study, one 
could argue that, assuming a linear relationship between 
the formation of the ultimate carcinogenic metabolite and 
the hepatoma incidence, intake levels in the Chinese pop-
ulation could be fivefold higher before reaching the same 
risk as expected for the Caucasian population. This is 
confirmed by the PBK model predictions that reveal that 
the amount of 1′-sulfooxyestragole formed within 24  h 
upon an intake of, respectively, 0.01 or 5 mg/kg bw for a 
Caucasian would be reached upon an estragole intake of, 
respectively, 0.05 or 25 mg/kg bw for a Chinese individ-
ual. Converting this five-fold difference in estragole bio-
activation to the MOE values presented above would still 
result in MOE values below 10,000 pointing at a prior-
ity for risk management also for the Chinese population. 
According to the national food safety standard for uses of 
food additives in China, estragole is allowed to be used 
in foods as synthetic flavoring substance and fennel oil 
is permitted to be used in foods as natural flavoring sub-
stance (NHFPC 2014a). The maximum levels of estragole 
present in foods are not well-regulated in China and thus 
may lead to a potential risk for the Chinese population 
when consuming estragole-containing food products.
It is important to note that the PBK model used in the 
present study was developed to predict the formation of 
the ultimate carcinogen metabolite, 1′-sulfooxyestragole. 
Further metabolic reactions of 1′-sulfooxyestragole such 
as conjugation with GSH, RNA, DNA, and other cellular 
macromolecules were not included in the PBK model. Pos-
sible ethnic differences in the capacity of DNA repair and 
reversibility of DNA-adduct formation may also be pre-
sent. For example, genetic polymorphisms in DNA repair 
genes ERCC1 and ERCC2/XPD, which are involved in 
the nucleotide excision repair pathway, have been identi-
fied (Yin et  al. 2005). Previous studies reported that the 
A-allele frequency of ERCC1 G19007A in the northeastern 
Chinese population was much lower compared with Cauca-
sian, indicating another genetic contribution to differences 
in sensitivity to genotoxic carcinogens between ethnic 
groups (Yin et al. 2005). The current PBK model could be 
extended to a PBD model by including DNA-adduct forma-
tion in hepatocytes from Chinese donors, which allows tak-
ing into account possible ethnic difference in DNA repair.
In summary, the present study elucidates a possible 
approach to determine the inter-ethnic human difference in 
bioactivation and detoxification of compounds of concern 
taking estragole as the model compound. The outcomes 
obtained clearly illustrate that PBK modeling is essential 
to integrate information on ethnic differences in the various 
metabolic conversions to enable prediction of  their com-
bined consequence for the bioactivation to the ultimate car-
cinogenic metabolite. The 4.5-fold difference in formation 
of the ultimate carcinogenic metabolite of estragole accom-
panied by similar rates of detoxification may indicate a 
lower risk of estragole for the Chinese population at similar 
levels of exposure. The study provides a proof of principle 
for how PBK modeling can identify ethnic sensitivity and 
provide a more refined risk assessment for a specific ethnic 
group for a compound of concern.
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